Arrieta Oscar, Campillo Carlos, Burgos Rubén, Celis Miguel Ángel, Llata Manuel De la, Domínguez Judith, Halabe José, Islas Sergio, Jasso Luis, Lifshitz Alberto, Moreno Mucio, Plancarte Ricardo, Reyes-Sánchez Alejandro, Ruiz-Argüelles Guillermo J, Soda Antonio, Verástegui Emma, Sotelo Julio
Academia Nacional de Medicina, Comité de Ética y Transparencia en la Relación Médico-Industria, Ciudad de México, México.
Gac Med Mex. 2019;155(3):319-321. doi: 10.24875/GMM.18004915.
Clinical research is the most important tool for the identification of diagnostic and therapeutic strategies that derive in higher efficacy and safety. Despite its significance, successful implementation of clinical research faces numerous difficulties, with one the most relevant being limited availability of resources for the performance of independent clinical trials. Generally, the pharmaceutical industry absorbs the costs associated with most clinical trials; however, this can generate dissociation between subjects of interest and health priorities when economic interest is the main driver of these protocols. In addition to the relevant role played by the pharmaceutical industry, it is important that government agencies favor adequate conditions, both in economic and regulatory aspects, for the implementation of independent clinical research that addresses subjects of medical and therapeutic interest, even if it does not generate corporate economic benefits.
临床研究是确定能带来更高疗效和安全性的诊断及治疗策略的最重要工具。尽管其意义重大，但临床研究的成功实施面临诸多困难，其中最相关的一个困难是开展独立临床试验的资源有限。一般来说，制药行业承担了大多数临床试验的相关费用；然而，当经济利益是这些试验方案的主要驱动力时，这可能会导致利益相关主体与健康优先事项之间产生脱节。除了制药行业所发挥的相关作用外，政府机构营造经济和监管方面的适当条件，以开展针对医学和治疗方面感兴趣主题的独立临床研究也很重要，即便这类研究不会产生企业经济效益。
